Literature DB >> 9178893

Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.

K J Sweeney1, B Sarcevic, R L Sutherland, E A Musgrove.   

Abstract

To investigate the possibility of differing roles for cyclins D1 and D2 in breast epithelial cells, we examined the expression, cell cycle regulation and activity of these two G1 cyclins in both 184 normal breast epithelial cells and T-47D breast cancer cells. Synchronisation studies in 184 cells demonstrated that cyclin D1 and cyclin D2 were differentially regulated during G1, with cyclin D2 abundance increasing by 3.7-fold but only small changes in cyclin D1 abundance observed. The functional consequences of increased cyclin D2 expression were examined in T-47D cells, which express no detectable cyclin D2. Induced expression of cyclin D2 resulted in increases in cyclin E expression, pRB phosphorylation and the percentage of cells in S-phase, while constitutive expression resulted in a consistent trend toward reduced dependence on serum for continued proliferation. Thus, cyclin D2 is a positive regulator of G1 progression in breast cells analogous to the well-documented effects of cyclin D1. Indeed, equimolar concentrations of inducible cyclin D1 and D2 resulted in quantitatively similar cell cycle effects. Marked divergence was found, however, in the CDKs activated by the two cyclins in breast epithelial cells. Cyclin D2 complexes contained a higher Cdk2/Cdk4 ratio than cyclin D1 complexes. The cyclin D2-associated kinase activity was largely inhibited by Cdk2-specific inhibitors and could phosphorylate histone H1, a substrate for Cdk2 but not for Cdk4 and Cdk6. Therefore, cyclin D2 preferentially activated Cdk2 in breast epithelial cells. In contrast, Cdk4 and Cdk6 were predominantly responsible for cyclin D1-associated kinase activity as previously reported. Thus, although cyclins D1 and D2 elicited similar effects on breast epithelial cell cycle progression they appeared to achieve this end via activation of different CDKs. This is the first evidence of cyclin D2 activating Cdk2 in mammalian cells thus providing further evidence that D-type cyclins are not necessarily redundant.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178893     DOI: 10.1038/sj.onc.1200951

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

Review 1.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells.

Authors:  M Meyyappan; H Wong; C Hull; K T Riabowol
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

3.  DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Authors:  Min Chen; Daniel Shabashvili; Akbar Nawab; Sherry X Yang; Lisa M Dyer; Kevin D Brown; Melinda Hollingshead; Kent W Hunter; Frederic J Kaye; Steven N Hochwald; Victor E Marquez; Patricia Steeg; Maria Zajac-Kaye
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

4.  Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells.

Authors:  F Santiago; E Clark; S Chong; C Molina; F Mozafari; R Mahieux; M Fujii; N Azimi; F Kashanchi
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.

Authors:  Marcelo L Rodriguez-Puebla; Paula L Miliani de Marval; Margaret LaCava; David S Moons; Hiroaki Kiyokawa; Claudio J Conti
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 7.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

8.  APC mutation and tumour budding in colorectal cancer.

Authors:  J R Jass; M Barker; L Fraser; M D Walsh; V L J Whitehall; B Gabrielli; J Young; B A Leggett
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

9.  B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest.

Authors:  Xishan Xiong; Yingwei Zhang; Xiang Gao; Zheyi Dong; Lin Li; Chengcheng Ji; Lili Fu; Xiaomin Luo; Hong Liu; Changlin Mei
Journal:  Invest New Drugs       Date:  2009-01-13       Impact factor: 3.850

10.  Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors.

Authors:  Majid Kheirollahi; Masoud Mehr-Azin; Naser Kamalian; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-01-14       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.